Moroxydine Hydrochloride | Medchemexpress

Total Page：16

File Type：pdf, Size：1020Kb

Moroxydine Hydrochloride | Medchemexpress

Inhibitors Product Data Sheet Moroxydine hydrochloride • Agonists Cat. No.: HY-B0420A CAS No.: 3160-91-6 Molecular Formula: C₆H₁₄ClN₅O • Molecular Weight: 207.66 Screening Libraries Target: Influenza Virus Pathway: Anti-infection Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro H2O : ≥ 100 mg/mL (481.56 mM) DMSO : 50 mg/mL (240.78 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 4.8156 mL 24.0778 mL 48.1556 mL Stock Solutions 5 mM 0.9631 mL 4.8156 mL 9.6311 mL 10 mM 0.4816 mL 2.4078 mL 4.8156 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (481.56 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (12.04 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (12.04 mM); Clear solution 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (12.04 mM); Clear solution BIOLOGICAL ACTIVITY Description Moroxydine hydrochloride (ABOB hydrochloride) is a synthetic antiviral compound chemically belonging to the series of the heterocyclic biguanidines.Target: Influenza VirusMoroxydine hydrochloride (ABOB hydrochloride) is an antiviral drug that was originally developed in the 1950s as an influenza treatment. It has potential applications against a number of RNA and Page 1 of 2 www.MedChemExpress.com DNA viruses [1]. Structurally moroxydine is a heterocyclic biguanidine. Moroxydine was reported in March 2014 that three kindergartens in two provinces of China had been found to be secretly dosing their students with moroxydine hydrochloride to try to prevent them from becoming ill. The kindergartens are paid only for the days that pupils attend and wanted to ensure that they maximised their earnings [2]. REFERENCES [1]. Sheppard, S., Moroxydine: the story of a mislaid antiviral. Acta Derm Venereol Suppl (Stockh), 1994. 183: p. 1-9. [2]. Moore, Malcolm. "China: All children to be given drug tests after schools caught medicating pupils". The Age. Retrieved 2014-03-20. McePdfHeight Caution: Product has not been fully validated for medical applications. For research use only. Tel: 609-228-6898 Fax: 609-228-5909 E-mail: [email protected] Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Page 2 of 2 www.MedChemExpress.com.

Copy Link

Recommended publications

Synthesis of Polycyclic Compounds with Antiviral Activity
Synthesis of polycyclic compounds with antiviral activity Eva Torres Costa ADVERTIMENT. La consulta d’aquesta tesi queda condicionada a l’acceptació de les següents condicions d'ús: La difusió d’aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d’investigació i docència. No s’autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d’un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s’autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora. ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB.
[Show full text]
Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
[Show full text]
Seminar2019 Paper 6 in Cell Solid Liquid Extraction.Pdf
Journal of Chromatography A, 1488 (2017) 10–16 Contents lists available at ScienceDirect Journal of Chromatography A jo urnal homepage: www.elsevier.com/locate/chroma Development and application of an in-cell cleanup pressurized liquid extraction with ultra-high-performance liquid chromatography-tandem mass spectrometry to detect prohibited antiviral agents sensitively in livestock and poultry feces a b b c b a Huizhen Wu , Jianmei Wang , Hua Yang , Guoqin Li , Yinhuan Zeng , Wei Xia , a,∗ b,∗ Zuguang Li , Mingrong Qian a College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, 310014, China b Institute of Quality and Standard for Agro-products, Zhejiang Academy of Agricultural Sciences, MOA Key Laboratory for Pesticide Residue Detection, Hangzhou, 310021, China c Institute of Animal Husbandry and Veterinary Science, Zhejiang Academy of Agricultural Science, Hangzhou 310021, China a r a t b i c l e i n f o s t r a c t Article history: An in-cell cleanup pressurized liquid extraction was developed to analyze prohibited antiviral agents in Received 12 September 2016 livestock and poultry feces. Extraction and cleanup were integrated into one step. The extraction was per- Received in revised form ◦ formed using methanol-acetonitrile (1:1, v/v) with 0.5% glacial acetic acid at 90 C, and 0.75 g of PSA was 24 December 2016 used as the adsorbent during the extraction procedure. Under optimal conditions, the average recoveries Accepted 26 January 2017 −1 for 11 antiviral drugs were 71.5–112.5% at three spiked levels (20, 40, and 100 ␮g kg ). The detection Available online 27 January 2017 limits and detection quantitations of the analysis method for the eleven antiviral drugs were 0.6–1.4 and −1 1.4–4.7 ␮g kg , respectively.
[Show full text]
Appendices: V Ervolgonderzoek Medicatieveiligheid
APPENDICES: V ERVOLGONDERZOEK MEDICATIEVEILIGHEID Dit is een bijlage bij het rapport Vervolgonderzoek Medicatieveiligheid en is opgesteld voor het Ministerie van VWS vanuit een samenwerkingsverband tussen het Erasmus MC (Rotterdam), NIVEL (Utrecht), Radboud UMC (Nijmegen) en PHARMO (Utrecht) Januari 2017 Versie 1.0 1 Appendices Hoofstuk 2: Onderzoek naar de mate van opvolging van HARM-Wrestling aanbevelingen (2009-2014) 2 Appendix 1 Appendix 1: Technische omzetting van HARM-Wrestling aanbevelingen naar indicatoren Algemene specificaties Tabel A1a. Bepaling van medicatiegebruik. Geneesmiddel of ATC-code geneesmiddelen groep Antidepressiva N06A Laag gedoseerd ASA B01AC06, B01AC08, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Benzodiazepinen N05CF, N05CD, N05BA of N05CC Beta-blokkers C07 Bisfosfonaten M05BA, M05BB, of M05XX Calcineurine remmers L04AA05 of L04AD01 Carbamazepine N03AF01 Corticosteroiden H02AB Co-trimoxazol J01EE01 Coxibs M01AH Diabetesmedicatie A10 Digoxine C01AA05 Glibenclamide A10BB01 of A10BD02 of A10BD04 H2RA A02BA Itraconazol J02AC02 Kaliumsparende diuretica C03DA, C03DB, of C03EA Kaliumverliezende diuretica C03A, C03B, C03E, C07B, C07CB03, C09BA, C09DA, C09XA52, C03C of C09DX01 Ketoconazol J02AB02 Niet-selectieve NSAID’s N02BA01, N02BA15, N02BA11, N02BA51, N02BA65 of M01A met uitzondering van M01AH, M01AX05, M01AX12, M01AX21, M01AX24, M01AX25 en M01AX26 Laxantia A06A, A02AA02, A02AA03, A02AA04, A06AC, A06AA, of A06AG Lisdiuretica C03C Macroliden J01FA of A02BD04 VKA B01AA Opioïden N02AA met uitzondering van N02AA55, N02AA59 en N02AA79, N02AB, N02AC, N02AD, N02AG, N02AE of N07BC01 Pentamidine P01CX01 PPI’s A02BC of M01AE52 RAS-remmers C09 Sotalol C07AA07 Spironolacton C03DA01 SSRI's N06AB, N06AX21 of N06AX16 Sulonylureumderivaten A10BB, A10BD02 of A10BD04 Thiazidediuretica C03A, C03B, C03EA, C07B, C09BA, C09DA, C09XA52, C09DX01 of C07CB03 TAR B01AC04, B01AC06, B01AC08, B01AC22, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Thienopyridine derivaten B01AC04, B01AC22 of B01AC30 3 Appendix 1 Tabel A1b.
[Show full text]
Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
[Show full text]
Informatics Update
http://druggablegenome.net/ http://datascience.unm.edu/ Tudor I. Oprea with contributions from Sorin Avram, Giovanni Bocci, Cristian Bologa, Oleg Ursu, Lars Juhl Jensen, Praveen Kumar, Vishal B. Siramshetty, and Gergely Zahoranszky-Kohalmi and many others Funding: U24 CA224370, U24 TR002278, U01 CA239108 (NIH) 4/14/2020 OHDSI Community Call Albuquerque, NM, via ZOOM . There are 3 main pillars at the root of successful drug discovery programs. Informatics, Data Science and Machine Learning (“AI” according to the hype cycle) are successfully used, as follows: . Diseases: Significant improvements in EMR processing, nosology, ontology, and EMR-based ML for Dx & mechanisms . Targets: Knowledge graph methods, coupled with ML, for biological discovery, target selection & validation . Drugs: From virtual screening to vaccine design, therapeutic modalities benefit from predictive methods across the board . IDG is developing methods applicable to each of these 3 areas Diseases image credit: Julie McMurry, Melissa Haendel (OHSU). All other images credit: Nature Reviews Drug Discovery 2/5/20 revision We curated 667 human genome-derived proteins and 226 pathogen-derived biomolecules through which 1,578 US FDA- approved drugs act. This set included 1004 orally formulated drugs as well as 530 injectable drugs (approved through June 2016). Data captured in DrugCentral (link) R. Santos et al., Nature Rev. Drug Discov. 2017, 16:19-34 link 2/4/20 revision U24 DK116195: GPCRs Bryan Roth, M.D., Ph.D. (UNC) Brian Shoichet, Ph.D. (UCSF) RFA-RM-16-026 U24 DK116214: Ion (DRGC) Lily Jan, Ph.D. (UCSF) Channels Michael T. McManus, Ph.D. (UCSF) U24 DK116204: Kinases Gary L. Johnson, Ph.D.
[Show full text]
Alphabetical Listing of ATC Drugs & Codes
Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
[Show full text]
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
[Show full text]
Longitudinal Analysis of the Utility of Liver Biochemistry in Hospitalised COVID-19 Patients As Prognostic Markers
medRxiv preprint doi: https://doi.org/10.1101/2020.09.15.20194985; this version posted September 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers. Authors: Tingyan Wang1,2*, David A Smith1,3*, Cori Campbell1,2*, Steve Harris1,4, Hizni Salih1, Kinga A Várnai1,3, Kerrie Woods1,3, Theresa Noble1,3, Oliver Freeman1, Zuzana Moysova1,3, Thomas Marjot5, Gwilym J Webb6, Jim Davies1,4, Eleanor Barnes2,3*, Philippa C Matthews3,7*. Affiliations: 1. NIHR Oxford Biomedical Research Centre, Big Data Institute, University of Oxford 2. Nuffield Department of Medicine, University of Oxford 3. Oxford University Hospitals NHS Foundation Trust 4. Department of Computer Science, University of Oxford 5. Oxford Liver Unit, Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals 6. Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge 7. Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust *Equal Contributions Corresponding Author: Professor Eleanor Barnes, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford, OX1 3SY, UK. Telephone: 01865 281547. Email: [email protected] Author Contributions: T.W, D.A.S, C.C., P.C.M and E.B contributed equally to this work. T.W, D.A.S and C.C performed the data analysis and wrote the manuscript and were supervised by E.B, P.C.M and J.D.
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
[Show full text]
易奇瑞/維建樂膜衣錠(Viekirax 及exviera)
105BTD03003_Viekirax及Exviera 財團法人醫藥品查驗中心 Center For Drug Evaluation 易奇瑞/維建樂膜衣錠 (Viekirax 及 Exviera) 醫療科技評估報告「藥物納入全民健康保險給付建議書-藥品專用」資料摘要藥品名稱 Viekirax 及 Exviera 成分 ombitasvir/paritaprevir/ ritonavir 及 dasabuvir 建議者瑞士商艾伯維藥品有限公司藥品許可證持有商瑞士商艾伯維藥品有限公司含量規格劑型 Viekirax : 12.5 mg ombitasvir/ 75 mg paritaprevir/ 50 mg ritonavir 膜衣錠。 Exviera：dasabuvir 250 mg 膜衣錠。主管機關許可適應症 Viekirax 適用於與 Exviera、ribavirin 併用(併用方式詳參劑量與投藥方法段)，以治療成人慢性 C 型肝炎基因型 1、4 之感染。 Exviera 適用於與 Viekirax、ribavirin 併用(併用方式詳參劑量與投藥方法段)，以治療成人慢性 C 型肝炎基因型 1 之感染。建議健保給付之適應 Viekirax 併用 Exviera 適用於治療成人慢性 C 型肝炎感染。症內容針對慢性 C 型肝炎不同基因型及其亞型、病患肝功能、合併用藥及治療週數，請見“健保給付條件建議”欄。註：C 型肝炎相關 ICD code： ICD-9-CM 070.44 Chronic hepatitis C with hepatic coma (ICD-10-CM B18.2) ICD-9-CM 070.54 Chronic hepatitis C without mention of hepatic coma (ICD-10-CM B18.2) ICD-9-CM 070.70 Unspecified viral hepatitis C (ICD-10-CM B19.20) ICD-9-CM V02.62 Hepatitis C carrier (ICD-10-CM Z22.52) 建議健保給付條件 □無 ■有 (1) C 型肝炎基因型 1a 型，無肝硬化病人：以 Viekirax+Exviera 併用 Ribavirin 治療共 12 週。 (2) C 型肝炎基因型 1a 型，有代償性肝硬化病人：以 Viekirax+Exviera 併用 Ribavirin 治療共 24 週。 (3) C 型肝炎基因型 1b 型，無肝硬化病人：以 Viekirax+Exviera 治療共 12 週。 (4) C 型肝炎基因型 1b 型，有代償性肝硬化病人：以 Viekirax+Exviera 併用 Ribavirin 治療共 12 週。 1/78 105BTD03003_Viekirax及Exviera 建議療程一般劑量：建議口服劑量為兩錠 Viekirax 12.5/75/50 mg 錠劑，每日一次(早上)，以及一錠 Exviera 250 mg 錠劑，每日兩次(早上與晚上)。最大劑量：兩錠 Viekirax 12.5/75/50 mg，兩錠 Exviera 250 mg (同一般劑量)。單一療程：治療 12 週。建議者自評是否屬突 □非突破創新新藥破創新新藥 ■突破創新新藥健保是否還有給付其 ■無同成分（複方）健保給付藥品他同成分藥品 □有，藥品名為，從民國年月日起開始給付醫療科技評估報告摘要摘要說明：一、參考品：如表一。二、主要醫療科技評估組織之給付建議：如表二。三、相對療效與安全性（人體健康）：
[Show full text]
View U.S. Patent Application Publication No. US-2020-0056988
1111111111111111 IIIIII IIIII 1111111111 11111 11111 111111111111111 IIIII IIIII IIIIII IIII 11111111 US 20200056988Al c19) United States c12) Patent Application Publication c10) Pub. No.: US 2020/0056988 Al Butz et al. (43) Pub. Date: Feb. 20, 2020 (54) METHOD OF DETERMINING THE Publication Classification EFFICACY OF ANTIMICROBIALS (51) Int. Cl. GOIN 2113504 (2006.01) (71) Applicant: Wisconsin Alumni Research GOIN 33/497 (2006.01) Foundation, Madison, WI (US) (52) U.S. Cl. CPC ....... GOIN 2113504 (2013.01); GOIN 33/497 (72) Inventors: Daniel Elmer Butz, Madison, WI (US); (2013.01) Ann P. O'Rourke, Madison, WI (US); Mark E. Cook, Madison, WI (US) (57) ABSTRACT A method of determining efficacy of an antimicrobial treat ment in a subject includes calculating a breath delta value (21) Appl. No.: 16/540,627 (BDV) for each of at least six breath samples acquired from the subject over a 24 hour period starting from when the subject has been administered the antimicrobial treatment, (22) Filed: Aug. 14, 2019 calculating a mean standard deviation of BDV (SD BDV) across the six or more breath samples; and determining that the antimicrobial treatment is effective when the SD BDV is Related U.S. Application Data less than or equal to 0.46, or determining that the antimi crobial treatment is ineffective when the SD BDV is greater (60) Provisional application No. 62/764,874, filed on Aug. than 0.46. Also included are methods of treating a subject in 16, 2018. need of antimicrobial treatment. r Ass~sse~.f~;·el;~!~i!lt;·~n~~·~1)···· i ,, --~----·--··--···············r··············•······-·······•_.•.•.•.•_.•.•.•.•_J________ ___.........,., ; Excluded (no:299) r- ➔@!~;;;:~=:· ~··· Consented for partidpatfon {ir=32) Wi!hdrawn: • Exdusionary Criteria (ri=3) • Withdrawn by lnve.stigator(n"'2) Analyzed {n:=27) , Excluded from analysis {inadequate breath samples} {n=7} • 20 Subjects Anaiyze<l: o 13 Male; 7 Femi.lie o 76.2% Caucasian: VU% African American: 9.5% Other o 19% 18-35 yfo; 33_3% 36-54 yfo; 33.3% 55-73 yfo: i4.3 74+ yto Patent Application Publication Feb.
[Show full text]